Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

Figure 1

Patient 1: platelet count (bar graph) and corresponding serum CA 125 (U/ml). Carboplatin AUC 3/paclitaxel 75 mg/m2 (white columns). Single agent carboplatin AUC 3 (hatched columns). Dose omission (black columns). Carboplatin AUC 2/paclitaxel 20 mg/m2 (diagonal lined column). Carboplatin AUC 3/paclitaxel 20 mg/m2 (striped column). Carboplatin AUC 4/paclitaxel 20 mg/m2 (hatched column). Serum CA 125 (solid line).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us